NASDAQ:ANCNANCHIANO THERAP/S Stock Price, Forecast & News

ANCHIANO THERAP/S's stock was trading at $0.8191 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ANCN stock has increased by 21.8% and is now trading at $0.9975.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ANCHIANO THERAP/S.

ANCHIANO THERAP/S (NASDAQ:ANCN) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.14.
View ANCHIANO THERAP/S's earnings history.

3 brokerages have issued twelve-month target prices for ANCHIANO THERAP/S's stock. Their forecasts range from $16.00 to $16.00. On average, they expect ANCHIANO THERAP/S's share price to reach $16.00 in the next year. This suggests a possible upside of 1,504.0% from the stock's current price.
View analysts' price targets for ANCHIANO THERAP/S.

News articles about ANCN stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
View the latest news about ANCHIANO THERAP/S.

Some companies that are related to ANCHIANO THERAP/S include KemPharm (KMPH), Provectus Biopharmaceuticals (PVCT), Kazia Therapeutics (KZIA), PLx Pharma (PLXP), Alimera Sciences (ALIM), Neurotrope (NTRP), Aptevo Therapeutics (APVO), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Spring Bank Pharmaceuticals (SBPH), Mateon Therapeutics (MATN), Cyclacel Pharmaceuticals (CYCC), Adial Pharmaceuticals (ADIL), IntelGenx Technologies (IGXT), Pharmaxis (PXSLY) and OHR Pharmaceutical (OHRP).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Amplify Energy (AMPY), Amplify Energy (AMPY), Algonquin Power & Utilities (AQN), BCE (BCE), Franklin Resources (BEN), Bank of Nova Scotia (BNS), British American Tobacco (BTI) and Carnival (CCL).

(ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANCN stock can currently be purchased for approximately $1.00.

ANCHIANO THERAP/S has a market capitalization of $7.40 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.

The official website for ANCHIANO THERAP/S is www.anchiano.com.

ANCHIANO THERAP/S's mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]